

Media Release

8 September 2017

NEW STUDY IN DIABETIC RETINOPATHY- INTERVIEW WITH PHARMAXIS CHIEF EXECUTIVE OFFICER

Pharmaceutical research company Pharmaxis (ASX: PXS) today released a video interview with Chief Executive Officer Gary Phillips discussing the announcement that Boehringer Ingelheim is initiating a Phase 2a study in a second disease indication for the drug it acquired from Pharmaxis in 2015.

The five minute video interview can be accessed via the following link:

<https://www.youtube.com/watch?v=OSB0fGkW5Kk>

#ends#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au